IL136665A0 - Mutants of endostatin, "em 1" having anti-angiogenic activity and methods of use thereof - Google Patents

Mutants of endostatin, "em 1" having anti-angiogenic activity and methods of use thereof

Info

Publication number
IL136665A0
IL136665A0 IL13666598A IL13666598A IL136665A0 IL 136665 A0 IL136665 A0 IL 136665A0 IL 13666598 A IL13666598 A IL 13666598A IL 13666598 A IL13666598 A IL 13666598A IL 136665 A0 IL136665 A0 IL 136665A0
Authority
IL
Israel
Prior art keywords
endostatin
methods
mutants
angiogenic activity
yeast expression
Prior art date
Application number
IL13666598A
Other languages
English (en)
Original Assignee
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital filed Critical Beth Israel Hospital
Publication of IL136665A0 publication Critical patent/IL136665A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
IL13666598A 1997-12-08 1998-12-08 Mutants of endostatin, "em 1" having anti-angiogenic activity and methods of use thereof IL136665A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6788897P 1997-12-08 1997-12-08
US8266398P 1998-04-22 1998-04-22
US10853698P 1998-11-16 1998-11-16
PCT/US1998/026057 WO1999029855A1 (en) 1997-12-08 1998-12-08 Mutants of endostatin, 'em 1' having anti-angiogenic activity and methods of use thereof

Publications (1)

Publication Number Publication Date
IL136665A0 true IL136665A0 (en) 2001-06-14

Family

ID=27371250

Family Applications (3)

Application Number Title Priority Date Filing Date
IL13666598A IL136665A0 (en) 1997-12-08 1998-12-08 Mutants of endostatin, "em 1" having anti-angiogenic activity and methods of use thereof
IL13666798A IL136667A0 (en) 1997-12-08 1998-12-08 Methods of producing anti-angiogenic proteins: endostatin, angiostatin or restin, using a pichia yeast expression system
IL13666898A IL136668A0 (en) 1997-12-08 1998-12-08 Restin and methods of use thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL13666798A IL136667A0 (en) 1997-12-08 1998-12-08 Methods of producing anti-angiogenic proteins: endostatin, angiostatin or restin, using a pichia yeast expression system
IL13666898A IL136668A0 (en) 1997-12-08 1998-12-08 Restin and methods of use thereof

Country Status (10)

Country Link
EP (3) EP1037985A1 (ko)
JP (3) JP2001526031A (ko)
KR (3) KR20010015867A (ko)
CN (3) CN1284134A (ko)
AT (1) ATE319840T1 (ko)
AU (3) AU742866B2 (ko)
CA (3) CA2313251A1 (ko)
DE (1) DE69833794D1 (ko)
IL (3) IL136665A0 (ko)
WO (3) WO1999029855A1 (ko)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1284134A (zh) * 1997-12-08 2001-02-14 贝斯以色列护理医疗中心 利用毕赤氏酵母表达系统生产抗生血管蛋白质∶制管张素,内抑制素或静息蛋白的方法
US6852691B1 (en) 1997-12-08 2005-02-08 Beth Israel Deaconess Medical Center Anti-angiogenic peptides and methods of use thereof
US6797488B1 (en) 1997-12-08 2004-09-28 Beth Israel Deaconess Medical Center Methods of producing anti-angiogenic proteins
WO2000017240A1 (de) * 1998-09-21 2000-03-30 Haemopep Pharma Gmbh Hmw-endostatin zur hemmung des wachstums von tumoren und von gefässwucherungen und zur diagnose von gefäss- und tumorerkrankungen
IT1312077B1 (it) 1999-04-15 2002-04-04 Univ Degli Studi Milano Polipeptidi ad attivita' antiangiogenica.
JP2001031586A (ja) * 1999-07-14 2001-02-06 Sunstar Inc 動脈硬化症及び動脈硬化症に起因する疾患の予防又は治療組成物
FR2803207B1 (fr) * 1999-12-30 2004-04-30 Aventis Pharma Sa Utilisation d'un vecteur comprenant un acide nucleique codant pour un facteur anti-angiogenique pour le traitement des neovascularisations corneennes
WO2001049316A2 (fr) * 1999-12-30 2001-07-12 Aventis Pharma S.A. Utilisation d'un vecteur comprenant un acide nucleique codant pour un facteur anti-angiogenique pour le traitement des neovascularisations corneennes
JP2004500087A (ja) * 2000-02-10 2004-01-08 ザイモジェネティクス，インコーポレイティド 抗−脈管形成性腸ペプチド、ｚｄｉｎｔ５
CN1311228A (zh) * 2000-03-02 2001-09-05 上海博德基因开发有限公司 一种新的多肽——人精子特异蛋白em1,em6－48和编码这种多肽的多核苷酸
EP1666595A1 (en) 2000-10-26 2006-06-07 Beth Israel Deaconess Medical Center, Inc. GAB2 (P97) gene and methods of use thereof
KR100579660B1 (ko) * 2003-08-18 2006-05-15 정인식 제미니바이러스 발현시스템을 이용한 재조합 신생혈관생성억제 단백질의 제조방법
DE602004015142D1 (de) * 2003-08-29 2008-08-28 Childrens Medical Center Antiangiogene peptide zur behandlung oder vorbeugung von endometriose
US7524811B2 (en) 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin
ES2325344B1 (es) * 2004-11-02 2010-06-09 Univ Madrid Autonoma Inhibidores de angiogenesis multifuncionales y multivalentes.
US8586544B2 (en) 2008-04-04 2013-11-19 Procell Therapeutics Inc. Cell-permeable endostatin recombinant protein, a polynucleotide encoding the same, and an anti-cancer preparation containing the same as an active component
US10647968B2 (en) * 2011-09-09 2020-05-12 Tsinghua University Endostatin mutants with mutations at ATP binding sites
EP2628748A1 (en) 2012-02-14 2013-08-21 Szilak Laboratories Bioinformatics & Molecule-Design Ltd. Angiostatin chimeras and uses thereof
CN104926933B (zh) * 2014-03-19 2018-09-07 北京仁和天通生物科技有限公司 Endostatin突变体、Endostatin突变体与聚乙二醇的交联物以及它们的应用
WO2016197018A1 (en) 2015-06-05 2016-12-08 Ibio, Inc. Endostatin fragments and variants for use in treating fibrosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945403A (en) * 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
JP3880064B2 (ja) * 1994-04-26 2007-02-14 ザ チルドレンズ メディカル センター コーポレイション アンジオスタチンおよび血管形成の抑制におけるその使用
JP3787157B2 (ja) * 1995-04-26 2006-06-21 ザ チルドレンズ メディカル センター コーポレイション アンジオスタチンフラグメント、アンジオスタチン凝集体および使用方法
CZ117798A3 (cs) * 1995-10-23 1998-08-12 The Children's Medical Center Corporation Antiangiogenní kompozice a způsoby léčby
WO1999016889A1 (en) * 1997-10-01 1999-04-08 G.D. Searle & Co. Fusion proteins comprising an angiostatin moiety and their use in anti-tumor treatment
WO1999026480A1 (en) * 1997-11-20 1999-06-03 Genetix Pharmaceuticals, Inc. Anti-angiogenic gene therapy vectors and their use in treating angiogenesis-related diseases
CN1284134A (zh) * 1997-12-08 2001-02-14 贝斯以色列护理医疗中心 利用毕赤氏酵母表达系统生产抗生血管蛋白质∶制管张素,内抑制素或静息蛋白的方法

Also Published As

Publication number Publication date
CN1322246A (zh) 2001-11-14
AU753889B2 (en) 2002-10-31
KR20010015869A (ko) 2001-02-26
CN1284134A (zh) 2001-02-14
ATE319840T1 (de) 2006-03-15
IL136668A0 (en) 2001-06-14
WO1999029878A2 (en) 1999-06-17
WO1999029856A1 (en) 1999-06-17
CN1284130A (zh) 2001-02-14
AU1718099A (en) 1999-06-28
CA2313251A1 (en) 1999-06-17
EP1038011B1 (en) 2006-03-08
WO1999029878A3 (en) 1999-09-16
EP1037985A1 (en) 2000-09-27
AU1806599A (en) 1999-06-28
KR20010015867A (ko) 2001-02-26
AU1808899A (en) 1999-06-28
CA2313705A1 (en) 1999-06-17
AU749904B2 (en) 2002-07-04
DE69833794D1 (de) 2006-05-04
CA2312287A1 (en) 1999-06-17
WO1999029855A1 (en) 1999-06-17
IL136667A0 (en) 2001-06-14
AU742866B2 (en) 2002-01-17
JP2002503449A (ja) 2002-02-05
KR20010015868A (ko) 2001-02-26
JP2001526031A (ja) 2001-12-18
JP2001526040A (ja) 2001-12-18
EP1038011A2 (en) 2000-09-27
EP1037983A1 (en) 2000-09-27

Similar Documents

Publication Publication Date Title
IL136665A0 (en) Mutants of endostatin, "em 1" having anti-angiogenic activity and methods of use thereof
MX9709472A (es) & -amilasa mutante.
WO1996022308A3 (en) Appetite suppression factor and related methods
IL129686A0 (en) Method for producing recombinant virus
ES2162132T3 (es) Polimerasa de adn termoestable procedente de thermoanaerobacter thermohydrosulfuricus y enzimas mutantes, de actividad exonucleasa suprimida asi obtenidos.
AU4010795A (en) Femoral intramedullary nail
NZ313625A (en) Process for stabilizing proteins in an acidic environment with a high-ester pectin
AU4085497A (en) 5-substituted and 5,5-disubstituted-3,4-dihydroxy-2(5H) -furanones and methods of use therefor
AU9574198A (en) Method of affinity cross-linking biologically active, immunogenic peptides to antibodies
WO1999021976A3 (en) Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
MY115054A (en) Rubber thread
GB2353531A (en) Conditional mutants of influenza virus M2 protein
AU1952497A (en) Novel antibody-cytokine fusion protein, and methods of making and using the same
AU6509898A (en) Activation of peptides
PL320328A1 (en) Method of producing a variant of nisin
AU4317597A (en) Hematopoietic stem cells and methods for generating such cells
EP0733057A4 (en) ORIGIN OF REPLICATION COMPLEX GENES, PROTEINS AND METHODS
AU6832094A (en) Expansins, proteins that catalyze plant cell wall expansion and weakening of paper fiber connections
AU5777696A (en) Candida heat shock protein, cdna and uses thereof
EP0672753A4 (en) MULTICLONING VECTOR, EXPRESSION VECTOR, AND PRODUCTION OF EXOGENOUS PROTEIN USING SAID EXPRESSION VECTOR
NZ334744A (en) Method for determining expression of aberrant forms of APC protein
IL115999A0 (en) Proteins having fibrinolytic and coagulation-inhibiting properties
IL135516A0 (en) Process for n-desmethylating erythromycins and derivatives thereof
AU3526200A (en) Generation of conditional yeast mutants, methods and reagents related thereto
AU7478098A (en) Methods of treatment using nbs-1, antibodies and proteins thereto, and uses of the antibodies